Can Nuedexta (dextromethorphan/quinidine) be co‑administered with sertraline?

Can Nuedexta and Sertraline Be Given Together?

Nuedexta (dextromethorphan/quinidine) and sertraline should generally not be co-administered due to significant pharmacokinetic drug interactions and increased risk of serotonin syndrome, though if combination therapy is deemed essential, close monitoring with dose reduction is required.

Primary Safety Concerns

Serotonin Syndrome Risk

• Concomitant administration of dextromethorphan (which has serotonin reuptake inhibition properties) with SSRIs like sertraline increases the risk of serotonin syndrome—a potentially life-threatening condition presenting with agitation, confusion, hyperthermia, muscle rigidity, and autonomic instability. 1, 2
• Dextromethorphan acts as a serotonin and norepinephrine reuptake inhibitor in addition to its NMDA receptor antagonism, creating additive serotonergic effects when combined with sertraline. 2, 3

Pharmacokinetic Drug Interaction

• A controlled drug-drug interaction study demonstrated that combining dextromethorphan/quinidine with paroxetine (an SSRI similar to sertraline) resulted in a 50% increase in dextromethorphan plasma exposure and a 40% increase in quinidine exposure when paroxetine was added to DM/Q therapy. 4
• The quinidine component of Nuedexta is a CYP2D6 inhibitor, and sertraline is partially metabolized by CYP2D6, creating bidirectional metabolic interference. 4, 2
• The incidence of adverse events increased substantially with combination therapy (from 30.8% with DM/Q alone to 83.3% following addition of paroxetine in the study). 4

Clinical Decision Algorithm

When Combination Is Absolutely Contraindicated

• Never combine if the patient is taking MAOIs or has discontinued MAOIs within the past 14 days. 1
• Avoid combination in patients with uncontrolled hypertension, as both agents can increase blood pressure and heart rate. 1
• Do not combine in patients with poorly controlled seizure disorders, as bupropion (not present in Nuedexta but relevant to DM combinations) lowers seizure threshold; dextromethorphan itself requires caution in seizure-prone patients. 1
• Avoid in patients with cardiac conduction abnormalities or those at risk for QT prolongation, given quinidine's proarrhythmic potential. 5

If Combination Therapy Is Considered Essential

• Trial each medication as monotherapy first before considering combination therapy to avoid interaction risks entirely while still providing effective treatment. 1
• Monitor closely for serotonin syndrome symptoms including mental status changes, autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (tremor, rigidity, myoclonus, hyperreflexia), and gastrointestinal symptoms. 1
• Reduce sertraline dose by 25–50% when initiating Nuedexta to account for the expected increase in SSRI plasma concentrations (extrapolated from the 30% increase in paroxetine exposure observed in controlled studies). 4
• Monitor blood pressure and heart rate at baseline and regularly throughout treatment, as both agents can cause cardiovascular effects. 1
• Assess for increased adverse events including dizziness, somnolence, nausea, and falls, which occur more frequently with combination therapy. 4, 5

Safer Alternative Strategies

• Consider alternative augmentation strategies such as atypical antipsychotics or mood stabilizers instead of combining two serotonergic agents. 1
• If treating depression, consider that dextromethorphan/quinidine has shown preliminary efficacy as monotherapy or adjunctive therapy in treatment-resistant depression (45% response rate in open-label trials), potentially allowing sertraline discontinuation rather than combination. 6, 7
• If treating pseudobulbar affect (the FDA-approved indication for Nuedexta), consider whether sertraline is essential or could be replaced with a non-serotonergic alternative. 3, 8

Critical Monitoring Parameters If Combination Proceeds

• Baseline assessment: Blood pressure, heart rate, ECG (if cardiac risk factors present), mental status, neuromuscular examination. 1, 5
• Weekly monitoring for first month: Serotonin syndrome symptoms, blood pressure, heart rate, adverse events. 4
• Ongoing monitoring: Monthly reassessment of necessity for combination therapy, with attempts to simplify regimen to monotherapy when clinically feasible. 1
• Drug interaction review: Ensure no additional CNS-active agents (≥3 total) are being used, as this dramatically increases fall risk. 9

Special Population Considerations

• Older adults: Exercise extreme caution, as the combination of multiple CNS-active agents increases fall and fracture risk; consider avoiding combination entirely in this population. 9, 10
• Hepatic impairment: Both agents require dose adjustment; combination therapy is particularly hazardous in moderate-to-severe hepatic impairment. 1
• Renal impairment: Dose reduction of both agents may be necessary; combination therapy increases complexity of dosing adjustments. 1